Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

The website changes raise concerns about “the interference of politics with the study and the practice” of science and ...

In this article, we are going to take a look at where Lexicon Pharmaceuticals ... Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and ...

IPC Indice de Precios Y Cotizaciones 51,357.31 302.40 0.59% ...